- Effects of Tamoxifen and Raloxifene on Memory and Other Cognitive Abilities: Cognition in the Study of Tamoxifen and Raloxifene
[作者:Legault, C; Maki, PM; Resnick, SM; Coker, L; Hogan, P; Bevers, TB; Shumaker, SA,期刊:Journal of clinical oncology, 页码:5144-5152 , 文章类型: Article,,卷期:2009年27-31]
- Purpose To compare the effects of two selective estrogen receptor modulators, tamoxifen and raloxifene, on global and domain-specific cognitive function. Patients and Methods The National Surgical Adjuvant Breast and Bow...
- Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer
[作者:Liu, MC; Shields, PG; Warren, RD; Cohen, P; Wilkinson, M; Ottaviano, YL; Rao, SB; Eng-Wong, J; Seillier-Moiseiwitsch, F; Noone, AM; Isaacs, C,期刊:Journal of clinical oncology, 页码:5153-5159 , 文章类型: Article,,卷期:2009年27-31]
- Purpose Five or more circulating tumor cells (CTCs) per 7.5 mL of blood predicts for poorer progression-free survival (PFS) in patients with metastatic breast cancer (MBC). We conducted a prospective study to demonstrate...
- Underuse of Breast Cancer Adjuvant Treatment: Patient Knowledge, Beliefs, and Medical Mistrust
[作者:Bickell, NA; Weidmann, J; Fei, KZ; Lin, JJ; Leventhal, H,期刊:Journal of clinical oncology, 页码:5160-5167 , 文章类型: Article,,卷期:2009年27-31]
- Purpose Little is known about why women with breast cancer who have surgery do not receive proven effective postsurgical adjuvant treatments. Methods We surveyed 258 women who recently underwent surgical treatment at six...
- Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow
[作者:Basso, G; Veltroni, M; Valsecchi, MG; Dworzak, MN; Ratei, R; Silvestri, D; Benetello, A; Buldini, B; Maglia, O; Masera, G; Conter, V; Arico, M; Biondi, A; Gaipa, G,期刊:Journal of clinical oncology, 页码:5168-5174 , 文章类型: Article,,卷期:2009年27-31]
- Purpose Speed of blast clearance is an indicator of outcome in childhood acute lymphoblastic leukemia (ALL). Availability of measurement of minimal residual disease (MRD) at an early time point with a reduced-cost method...
- Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
[作者:Schultz, KR; Bowman, WP; Aledo, A; Slayton, WB; Sather, H; Devidas, M; Wang, C; Davies, SM; Gaynon, PS; Trigg, M; Rutledge, R; Burden, L; Jorstad, D; Carroll, A; Heerema, NA; Winick, N; Borowitz, MJ; Hunger, SP; Carroll, WL; Camitta, B,期刊:Journal of clinical oncology, 页码:5175-5181 , 文章类型: Article,,卷期:2009年27-31]
- Purpose Imatinib mesylate is a targeted agent that may be used against Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), one of the highest risk pediatric ALL groups. Patients and Methods We eval...
- Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803
[作者:Arndt, CAS; Stoner, JA; Hawkins, DS; Rodeberg, DA; Hayes-Jordan, AA; Paidas, CN; Parham, DM; Teot, LA; Wharam, MD; Breneman, JC; Donaldson, SS; Anderson, JR; Meyer, WH,期刊:Journal of clinical oncology, 页码:5182-5188 , 文章类型: Article,,卷期:2009年27-31]
- Purpose The purpose of this study was to compare the outcome of patients with intermediate-risk rhabdomyosarcoma (RMS) treated with standard VAC (vincristine, dactinomycin, and cyclophosphamide) chemotherapy to that of p...
- Young Adults With Acute Lymphoblastic Leukemia Have an Excellent Outcome With Chemotherapy Alone and Benefit From Intensive Postinduction Treatment: A Report From the Children's Oncology Group
[作者:Nachman, JB; La, MK; Hunger, SP; Heerema, NA; Gaynon, PS; Hastings, C; Mattano, LA; Sather, H; Devidas, M; Freyer, DR; Steinherz, PG; Seibel, NL,期刊:Journal of clinical oncology, 页码:5189-5194 , 文章类型: Article,,卷期:2009年27-31]
- Purpose Patients 16 to 21 years of age with acute lymphoblastic leukemia (ALL) have an inferior outcome compared with younger children, leading some medical oncologists to advocate allogeneic stem-cell transplantation in...
- Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
[作者:Cilloni, D; Renneville, A; Hermitte, F; Hills, RK; Daly, S; Jovanovic, JV; Gottardi, E; Fava, M; Schnittger, S; Weiss, T; Izzo, B; Nomdedeu, J; van der Heijden, A; van der Reijden, BA; Jansen, JH; van der Velden, VHJ; Ommen, H; Preudhomme, C; Saglio, G; Grimwade, D,期刊:Journal of clinical oncology, 页码:5195-5201 , 文章类型: Article,,卷期:2009年27-31]
- Purpose Risk stratification in acute myeloid leukemia (AML) is currently based on pretreatment characteristics. It remains to be established whether relapse risk can be better predicted through assessment of minimal resi...
- IKZF1 (Ikaros) Deletions in BCR-ABL1-Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report
[作者:Martinelli, G; Iacobucci, I; Storlazzi, CT; Vignetti, M; Paoloni, F; Cilloni, D; Soverini, S; Vitale, A; Chiaretti, S; Cimino, G; Papayannidis, C; Paolini, S; Elia, L; Fazi, P; Meloni, G; Amadori, S; Saglio, G; Pane, F; Baccarani, M; Foa, R,期刊:Journal of clinical oncology, 页码:5202-5207 , 文章类型: Article,,卷期:2009年27-31]
- Purpose The causes of the aggressive nature of BCR-ABL1-positive adult acute lymphoblastic leukemia (ALL) are unknown. To identify, at the submicroscopic level, oncogenic lesions that cooperate with BCR-ABL1 to induce AL...
- 5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen
[作者:O'Brien, S; Moore, JO; Boyd, TE; Larratt, LM; Skotnicki, AB; Koziner, B; Chanan-Khan, AA; Seymour, JF; Gribben, J; Itri, LM; Rai, KR,期刊:Journal of clinical oncology, 页码:5208-5212 , 文章类型: Article,,卷期:2009年27-31]
- Purpose A randomized trial of oblimersen plus fludarabine/cyclophosphamide (OBL-FC; n = 120) versus FC (n = 121) was conducted in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). The primary end poin...
- Phase II Study of Yttrium-90-Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma
[作者:Wang, M; Oki, Y; Pro, B; Romaguera, JE; Rodriguez, MA; Samaniego, F; McLaughlin, P; Hagemeister, F; Neelapu, S; Copeland, A; Samuels, BI; Loyer, EM; Ji, Y; Younes, A,期刊:Journal of clinical oncology, 页码:5213-5218 , 文章类型: Article,,卷期:2009年27-31]
- Purpose This phase II trial evaluated the safety and efficacy of yttrium-90 (Y-90)-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma (MCL). Patients and Methods Patients with relapsed or r...
- New Lesions Detected by Single Nucleotide Polymorphism Array-Based Chromosomal Analysis Have Important Clinical Impact in Acute Myeloid Leukemia
[作者:Tiu, RV; Gondek, LP; O'Keefe, CL; Huh, J; Sekeres, MA; Elson, P; McDevitt, MA; Wang, XF; Levis, MJ; Karp, JE; Advani, AS; Maciejewski, JP,期刊:Journal of clinical oncology, 页码:5219-5226 , 文章类型: Proceedings Paper,,卷期:2009年27-31]
- Purpose Cytogenetics is the primary outcome predictor in acute myeloid leukemia (AML). Metaphase cytogenetics (MC) detects an abnormal karyotype in only half of patients with AML, however. Single nucleotide polymorphism ...
- Primary Testicular Diffuse Large B-Cell Lymphoma: A Population-Based Study on the Incidence, Natural History, and Survival Comparison With Primary Nodal Counterpart Before and After the Introduction of Rituximab
[作者:Gundrum, JD; Mathiason, MA; Moore, DB; Go, RS,期刊:Journal of clinical oncology, 页码:5227-5232 , 文章类型: Article,,卷期:2009年27-31]
- Purpose We performed a population-based study of primary testicular diffuse large B-cell lymphoma (DLBCL) in the United States to determine its incidence and survival trends, prognostic factors, and clinical outcome comp...
- Prevalence, Natural Course, and Risk Factors of Insomnia Comorbid With Cancer Over a 2-Month Period
[作者:Savard, J; Villa, J; Ivers, H; Simard, S; Morin, CM,期刊:Journal of clinical oncology, 页码:5233-5239 , 文章类型: Article,,卷期:2009年27-31]
- Purpose This study aimed to assess the prevalence, natural course, and risk factors of insomnia comorbid with cancer over a 2-month period. Patients and Methods All patients scheduled to receive a curative surgery for a ...
- Identification and Validation of a Gene Expression Signature That Predicts Outcome in Adult Men With Germ Cell Tumors
[作者:Korkola, JE; Houldsworth, J; Feldman, DR; Olshen, AB; Qin, LX; Patil, S; Reuter, VE; Bosl, GJ; Chaganti, RSK,期刊:Journal of clinical oncology, 页码:5240-5247 , 文章类型: Article,,卷期:2009年27-31]
- Purpose Germ cell tumor (GCT) is the most common malignancy in young adult men. Currently, patients are risk-stratified on the basis of clinical presentation and serum tumor markers. The introduction of molecular markers...
- Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non-Small-Cell Lung Cancer
[作者:Lee, SM; Rudd, R; Woll, PJ; Ottensmeier, C; Gilligan, D; Price, A; Spiro, S; Gower, N; Jitlal, M; Hackshaw, A,期刊:Journal of clinical oncology, 页码:5248-5254 , 文章类型: Proceedings Paper,,卷期:2009年27-31]
- Purpose Cancers rely on angiogenesis for their growth and dissemination. We hypothesized that thalidomide, an oral antiangiogenic agent, when combined with chemotherapy, and as maintenance treatment, would improve surviv...
|